ReviewAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2025
KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know.
Review in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of jinlida granule in the treatment of diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2026Pooled it
- Kidney failure risk equation and early renal risk in adults with sickle cell disease: comparison with KDIGO classification using measured GFR.Renal failure · 2026Article
- Tubular dysfunction in stable adult sickle cell patients in Kinshasa: prevalence and associated factors - a cross-sectional study.Renal failure · 2026Article
- Recommendations for the management of frailty in chronic kidney disease: a consensus report.Nature reviews. Nephrology · 2026Review
- A Study on Predicting Split Renal Function Using Renal Blood Flow Weighted Estimated Glomerular Filtration Rate From Arterial Spin Labeling MRI.Journal of magnetic resonance imaging : JMRI · 2026Article
- Studying the Comorbidity of Impaired eGFR With Diabetes, Hypertension, and Cardiovascular Diseases in the Tabari Cohort Population.Public health challenges · 2026Article
- A landscape of metabolic burden and its cardiovascular impact across the adult lifespan: a prospective cohort study of 7.5 million people in Northwestern China.The Lancet regional health. Western Pacific · 2026Article
- Fruits, Vegetables, and Legumes: Harnessing the Gut-Kidney Axis in Hypertensive Chronic Kidney Disease.Foods (Basel, Switzerland) · 2026Review
- Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease.Basic & clinical pharmacology & toxicology · 2026Article
- Serum profile of IL-29, IL-41, and raftlin in microvascular complications of type 2 diabetes mellitus.Scientific reports · 2026Article
- Multimodal Magnetic Resonance Imaging in Diabetic Kidney Disease: From Pathophysiological Insights to Clinical Applications.Diagnostics (Basel, Switzerland) · 2026Review
- Increased Risk of Intraocular Pressure-Lowering Treatment in Patients with End-Stage Renal Disease Undergoing Hemodialysis.Ophthalmology. Glaucoma · 2026Article
- Article
- International Union of Basic and Clinical Pharmacology. CXXI. Apelin receptor pharmacology in the human cardiovascular system and emerging clinical applications.Pharmacological reviews · 2026Review
- Factors Influencing Intraocular Pressure Elevation During Hemodialysis.Translational vision science & technology · 2026Observational
- Review
- Kidney function decline in working-age adults with cancer diagnosis: A study utilizing claims and health checkup data.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Selected Parameters Which Support the Laboratory Diagnosis of Cardiovascular-Kidney-Metabolic Syndrome in the Light of Current Guidelines: A Narrative Review.Journal of clinical medicine · 2026Review
- Wound healing outcomes in diabetic kidney disease patients receiving SGLT2 inhibitor therapy: a prospective propensity score-matched cohort study.Frontiers in endocrinology · 2026Article
- Association of estimated glomerular filtration rate and in-hospital mortality in patients hospitalized for heart failure: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo review the key updates in the 2024 KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease (CKD) and highlight the essential role of pharmacists in implementing these recommendations. SUMMARY: The updated guideline introduces significant changes in CKD management, including the use of validated equations for estimating glomerular filtration rate (GFR) for drug dosing, with incorporation of serum cystatin C into GFR estimates for specific patient populations, and an emphasis on a comprehensive approach to delay disease progression. The guideline recommends sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy for kidney disease with proteinuria, with or without diabetes, renin-angiotensin-aldosterone system inhibitors (RAASi) blood pressure control and proteinuria management, and statins to reduce the risk of atherosclerotic cardiovascular disease. New evidence supports the use of finerenone in patients with type 2 diabetes and CKD, and GLP-1 receptor agonists for their kidney-protective effects. The guidelines also emphasize the importance of nephrotoxin stewardship and prevention of acute kidney injury through patient education on sick day medication management.
conclusionPharmacists play a crucial role in implementing these updated guidelines through comprehensive medication management, nephrotoxin stewardship, drug dosing adjustments, and patient education. Their involvement in interprofessional care teams is essential for optimizing health outcomes in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.